Business Context and Reporting Period
This Form 8-K filing by OrthoPediatrics Corp. (KIDS) covers events occurring on November 2, 2021, and November 3, 2021. The report details amendments to the Non-Employee Director Compensation Policy effective January 1, 2022, and changes to the Board of Directors composition.
Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on governance and compensation matters.
Material Changes
Director Compensation Policy Amendments
- Restricted Stock Grant: Modified from a fixed 1,400 shares to a value equivalent to $75,000 based on the share price at the annual shareholder meeting.
- Quarterly Meeting Fee: Increased from $9,375 to $18,750 per meeting attended.
- Committee Chair Fees: Increased from $3,000 to $5,000 annually for the Chairperson of the Board, Compensation Committee, or Corporate Governance Committee.
- Audit Committee Chair Fee: Increased from $3,000 to $10,000 annually.
Board of Directors Changes
- Retirement: Bernie Berry, III retired from the Board effective November 3, 2021, after 12 years of service. The retirement was not due to any disagreement with the Company.
- Appointment: David R. Bailey, the Company's President and CEO, was appointed to fill the vacancy. He will serve in the Class of Directors expiring in 2024 and will not serve on any committees.
- Compensation for New Director: As an employee director, Mr. Bailey will receive no compensation for his director services and will not participate in the Non-Employee Director Compensation Policy.
- Retirement Benefits: Mr. Berry was granted an additional 2,119 shares of common stock, and the vesting of his remaining restricted stock grants was accelerated.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, outlook, management commentary on operations, or discuss specific risks and contingencies beyond the standard disclosure of the compensation policy changes and board transition.
Key Facts for Investor Verification
- Verify the impact of the increased director compensation on future equity dilution and cash expenses.
- Confirm the terms of the accelerated vesting for the retiring director, Bernie Berry, III.
- Review the Company's Definitive Proxy Statement (Schedule 14A) filed on April 16, 2021, for background on the newly appointed director, David R. Bailey.
- Note that the CEO now serves as a director but receives no additional compensation for that role.